Cleary Journeys Seamlessly Integrates Onboarding and Employee Lifecycle Management Functions into Cleary’s Modern Intranet Platform – Enabling Automated, Personalized, and Scalable Culture Integration from day one. SAN FRANCISCO, March 11, 2024 /PRNewswire/ — Cleary, the digital employee experience platform for distributed teams, is excited to unveil ‘Cleary Journeys,’ a customizable, automated employee lifecycle management system… Continue reading Redefining the Intranet for the Era of Hybrid Work: Announcing Cleary Journeys for Employee Onboarding and Lifecycle Management
Category: Newswire
Transforming Safety: AvaWatz is set to Revolutionize Robotics Industries With its Trusted AI Platform
DALLAS, March 11, 2024 /PRNewswire/ — AvaWatz Company (“AvaWatz”), a leading-edge AI company at the forefront of collaborative robotics, proudly announces the launch of its capital raise campaign on the StartEngine platform https://www.startengine.com/offering/avawatz. With a mission to liberate humans from high-risk and tedious tasks, AvaWatz is set to revolutionize industries with its trusted AI platform.… Continue reading Transforming Safety: AvaWatz is set to Revolutionize Robotics Industries With its Trusted AI Platform
Questel erreicht mit der strategischen Übernahme von qatent einen neuen Meilenstein für KI-gestützte Lösungen für geistiges Eigentum.
PARIS, 11. März 2024 /PRNewswire/ — Questel, ein weltweit führender Anbieter von Management- und Technologiedienstleistungen für geistiges Eigentum (IP), ist stolz, die Übernahme von qatent bekannt zu geben, einem Technologieunternehmen, dessen Einsatz künstlicher Intelligenz (KI) neue Wege im IP-Bereich beschritten hat Sektor. Die Übernahme von qatent durch Questel stellt einen Schlüsselbestandteil seiner Strategie dar, KI-gesteuerte Lösungen… Continue reading Questel erreicht mit der strategischen Übernahme von qatent einen neuen Meilenstein für KI-gestützte Lösungen für geistiges Eigentum.
Questel Achieves New Milestone for AI-Elevated Intellectual Property Solutions with Strategic Acquisition of qatent
PARIS, March 11, 2024 /PRNewswire/ — Questel, a global leader in intellectual property management solutions, is proud to announce the acquisition of qatent, a tech company whose use of artificial intelligence (AI) has broken new ground in the IP sector. Questel’s acquisition of qatent represents a key component of its strategy to integrate AI-driven solutions… Continue reading Questel Achieves New Milestone for AI-Elevated Intellectual Property Solutions with Strategic Acquisition of qatent
Questel Achieves New Milestone for AI-Elevated Intellectual Property Solutions with Strategic Acquisition of qatent
PARIS, March 11, 2024 /PRNewswire/ — Questel, a global leader in intellectual property management solutions, is proud to announce the acquisition of qatent, a tech company whose use of artificial intelligence (AI) has broken new ground in the IP sector. Questel’s acquisition of qatent represents a key component of its strategy to integrate AI-driven solutions… Continue reading Questel Achieves New Milestone for AI-Elevated Intellectual Property Solutions with Strategic Acquisition of qatent
Questel franchit une nouvelle étape dans l’utilisation de l’IA en gestion de la propriété intellectuelle grâce à l’acquisition stratégique de qatent
PARIS, 11 mars 2024 /PRNewswire/ — Questel, leader mondial en gestion de la propriété intellectuelle (PI), est fier d’annoncer l’acquisition de qatent, une entreprise technologique dont l’utilisation de l’intelligence artificielle (IA) permet de franchir un cap dans la gestion des actifs de propriété intellectuelle. L’acquisition de qatent par Questel est une étape clé de sa… Continue reading Questel franchit une nouvelle étape dans l’utilisation de l’IA en gestion de la propriété intellectuelle grâce à l’acquisition stratégique de qatent
Congressional “Minibus” Includes Historic Funding for MDMA-Assisted Therapy Trials
To combat PTSD and Veteran suicide, Congress directs the VA to fund nationwide trials of FDA-designated “Breakthrough Therapies,” including MDMA-Assisted Therapy. WASHINGTON, March 11, 2024 /PRNewswire/ — Healing Breakthrough, the leading federal advocacy group for veteran access to MDMA-assisted therapy (MDMA-AT), celebrates the achievement of its FY24 advocacy goal: securing the first-ever Congressional appropriation for large-scale,… Continue reading Congressional “Minibus” Includes Historic Funding for MDMA-Assisted Therapy Trials
VERSUNI ANNONCE UN CHANGEMENT DE DIRECTION
Véronique Pauwels a été nommée nouvelle présidente-directrice générale ; elle apporte une compréhension approfondie du paysage des consommateurs et une vaste expérience dans la mise en œuvre de plans de création de valeur axés sur l’innovation pour permettre à Versuni de franchir une nouvelle étape de croissance AMSTERDAM, 11 mars 2024 /PRNewswire/ — Versuni, l’un des… Continue reading VERSUNI ANNONCE UN CHANGEMENT DE DIRECTION
Vuse y la iniciativa impulsada por el cambio del equipo McLaren de Fórmula 1 hacen su debut en Japón
LONDRES, 11 de marzo de 2024 /PRNewswire/ — Vuse, la marca de vapeo número uno a nivel mundial*, y el equipo McLaren de Fórmula 1, celebran hoy el debut de Driven by Change en Japón, anunciando una asociación de un año de duración que mejorará su carrera con un artista japonés emergente. Continue Reading VUSE… Continue reading Vuse y la iniciativa impulsada por el cambio del equipo McLaren de Fórmula 1 hacen su debut en Japón
InnoGI Technologies Awarded Contract to Provide tiny-TIMsg Mimicking Human GUT (SurroGUT™) to U.S. Food and Drug Administration for Advanced Drug Absorption Research
DELFT, Netherlands, March 11, 2024 /PRNewswire/ — InnoGI Technologies, formerly The TIM Company, announced today that The U.S. Food and Drug Administration (FDA) acquired a tiny-TIMsg System. This system is part of InnoGI Technology’s SurroGUT™ platform, which provides invitro gastrointestinal research solutions. The funding for this acquisition was enabled through FDA contract #75F40123P00476. In the… Continue reading InnoGI Technologies Awarded Contract to Provide tiny-TIMsg Mimicking Human GUT (SurroGUT™) to U.S. Food and Drug Administration for Advanced Drug Absorption Research